LIMN Liminatus Pharma, Inc.

Nasdaq liminatuspharma.com


$ 1.39 $ -0.06 (-4.14 %)    

Thursday, 30-Oct-2025 15:55:01 EDT
QQQ $ 626.49 $ -5.53 (-0.87 %)
DIA $ 475.08 $ 0.93 (0.2 %)
SPY $ 680.25 $ -3.59 (-0.52 %)
TLT $ 90.57 $ 0.17 (0.19 %)
GLD $ 369.98 $ 4.88 (1.34 %)
$ 1.42
$ 1.45
$ 1.39 x 700
$ 1.40 x 54
$ 1.33 - $ 1.70
$ 1.11 - $ 33.66
862,189
na
33.09M
$ -1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-04-2025 06-30-2025 10-Q
2 05-31-2025 03-31-2025 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), La Palma, CA, a clinical-stage immuno-oncology company developing next-generation CD47-bl...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. has entered into a Memorandum of Understanding (MOU) to form a research and development consortium with ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION